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ABSTRACT 
 
We investigate the effect of both silver-lined (Silverline®, Spiegelberg, GMBH & Co.) and 
barium-impregnanted (EDM, Medtronic) lumbar catheters on concentrations of Aβ1-42 and T-
tau in CSF.  
 
CSF was collected from individuals of unknown disease via lumbar puncture (LP). CSF was 
thawed at 21°C CSF and and centrifuged for 5 minutes. A volume of 800uL was injected into 
(1) 2ml Sarsted aliquot (control), (2) barium-lined LD 80cm (3) silver-lined LD 80cm. CSF was 
collected through an LD over 3 different time periods: 30 seconds, 1 minute and 5 minutes 
(drain clamped before allowing CSF to drain). CSF was then collected into 2ml Sarsted aliquots. 
Each test was repeated three times per tube type, and per time protocol. Mean CSF 
concentrations (pg/ml) were corrected for total protein.  
 
A maxium reduction of Aβ1-42 pg/ml of 21.8% and 21.5% for barium-impregnated and silver-
lined catheters respectively, compared to control CSF that did not pass through a catheter. If 
the CSF was imediately sampled from the drain, the reduction was less, being 12.4% and 
5.00% for barium-impregnated and silver-lined catheters respectively, however this reduction 
was still signfiicant. T-tau levels were not significantly altered. 
 
Adsorption of Aβ peptides to the luminal surface of lumbar drains needs accounting for when 
interpreting concentrations, to prevent misleading diganosis or inaccurate results.  
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tau; AB1-42; cerebrospinal fluid (CSF); neurodegenerative markers 
 
  
 
 
 
1. INTRODUCTION 
 
The proteins Tau and Aβ1-42 are two conventionally measured cerebrospinal fluid (CSF) 
biomarkers that can assist with the diagnosis of neurodegenerative disease. In Alzheimer’s 
disease a high CSF total-tau (T-tau) concentration reflects neuroaxonal degeneration/injury 
and low CSF Aβ1-42 correlates with senile plaque pathology [1,2].  
 
There is evidence that these markers could be useful in the diagnosis of NPH. In NPH, lumbar 
CSF levels of Tau and Aβ1-42 are typically low or low/normal (respectively), and could 
potentially discriminate from Alzheimer’s disease, in addition to being a putative prognostic 
marker for shunt responsiveness [3-6].  
 
When measured in the context of investigating NPH, CSF is usually sampled from the lumbar 
drain, in-situ as part of the diagnostic protocol [7,8]. Increasingly lumbar drains are also being 
used to research rostrocaudal gradients of neurodegenerative markers, or within a study 
protocol method to obtain longitudinal biomarker results (to avoid multiple lumbar punctures) 
[9-11]. 
 
CSF transfer between collection tubes can reduce the overall concentration of Aβ1-42 by 25%, 
due to adsorption to the ionic surfaces [12]. It is unclear if the same effect is observed when 
CSF is sampled from lumbar drain.   
 
We investigate the effect of both silver-lined (Silverline®, Spiegelberg, GMBH & Co.) and 
barium-impregnanted (EDM, Medtronic) lumbar catheters, vs. lumbar puncture on 
concentrations of Aβ1-42 and T-tau in CSF.  
 
2. METHOD  
 
Collection of CSF 
CSF was collected from two anonymous individuals of unknown disease via lumbar puncture 
(LP). CSF sample collection and storage methods were all in accordance with the consensus 
guidelines for CSF biobanking [13].  
 
 
 
Lumbar drain testing 
CSF was thawed at 21°C and centrifuged for 5 minutes. A volume of 800uL was injected into 
(1) 2ml Sarsted aliquot (control), (2) barium-lined LD 80cm (3) silver-lined LD 80cm. CSF was 
collected through a LD over 3 different time periods: 30 seconds, 1 minute and 5 minutes (drain 
clamped before allowing CSF to drain). CSF was then collected into 2ml aliquots (Sarstedt, 
Numbrecht, Germany). Each test was repeated three times per tube type, and per time 
protocol. 
 
Electrochemiluminescent immunoassay analysis  
Samples underwent biochemical and enzyme-linked immunosorbent (ELISA) analysis to 
measure concentrations of T-tau (INNOTEST hTAU ELISA, Fujirebio, Ghent), Aβ-42 
(INNOTEST β-amyloid (1-42), Fujirebio, Ghent). Total protein (TP) was measured as a control. 
A technician prospectively recorded levels of T-tau and Aβ-42 and was blinded to the tube type 
and dwell time.  
 
Longitudinal stability in the measurements was ascertained using an elaborate programme of 
internal quality control (QC) samples. The laboratory also takes part in the Alzheimer’s 
Association external QC programme for CSF biomarkers. Intra- and inter-assay coefficients of 
variation were 12-15% for Aβ1-42 and 3-12% for T-tau. 
 
Statistical analysis 
Mean CSF concentrations (pg/ml) were corrected for TP. Measurement of uncertainly (MU) in 
T-tau and AB1-42 is 3-47 and 9-17 pg/ml respectively. ANOVA (Geisser-Greenhouse 
correction) determined significance.  
 
3. RESULTS 
 
A Percentage reduction in Aβ1-42 pg/ml for barium-impregnated catheters and silver-lined 
catheters are 9.3% (range 7.4-11.1%, taking MU corrections into account) and 20.5% (range 
11.3-22.3) respectively, when CSF had dwelled in the catheter tube for 5 minutes (table 1). 
This reduction was significant in the silver-line tubing group. T-tau levels were not significantly 
altered.  
 
Table 1.  Five min. CSF dwell time and neurogenertaive marker concentrations (sample 1) 
 
 
 Control  
 
Barium LD 
mean (n=3) 
Silver LD 
mean (n=3) 
p-value (after MU 
correction) 
T-tau pg/ml 638  631  714  0.222 
Aβ1-42 pg/ml 1737 1575 1381 0.003 
 
A significant percentage reduction in Aβ1-42 pg/ml was observed for both barium-
impregnated catheters and silver-lined catheters, dropping by 21.8% (range 11.6-26.9%) and 
21.5% (range 11.8-30.1%) respectively, when CSF had dwelled in the catheter tube for 1 
minute (table 2). T-tau levels were not significantly altered.  
 
Table 2.  One min. CSF dwell time and neurogenertaive marker concentrations (sample 2) 
 Control Barium LD 
 
Silver LD 
 
p-value (after MU 
correction) 
T-tau pg/ml 385  317  376  0.003  
Aβ1-42 pg/ml 922   721 724 0.001  
 
Although the percentage reduction in Aβ peptide was less, there was still significant reduction 
in Aβ1-42 pg/ml for both barium-impregnated catheters and silver-lined catheters, dropping by 
12.4% (range 8.68-16.1%) and 5.00% (0.97-8.67%) respectively, when CSF had been pulled 
straight through the lumbar catheter tube in over 30-50 seconds (table 3). T-tau levels were not 
significantly altered. 
 
Table 3. Less than 1 min. CSF dwell time and neurogenertaive marker concentrations 
(sample 2) 
 Control  Barium LD Silver LD 
 
p-value (after MU 
correction) 
T-tau pg/ml 385  305 361 0.999 
Aβ1-42 pg/ml 922 808 879 0.040 
 
4. DISCUSSION  
 
There are no publications demonstrating the clinical or research implications of analysing CSF 
samples for neurodegenerative proteins, when taken from a lumbar drain. We demonstrate that 
 
 
CSF taken from lumbar drains can have artificially low Aβ1-42 concentrations (regardless of 
the drain being barium or silver lined).  
 
CSF collection methods have been previosuly scrutinised regarding this issue. It has been 
found that aspiration of CSF (as opposed to drip collection) does not alter the levels of relevant 
proteins [14]. Furthermore, transfer at room temperature (and not on ice), and transfer times 
over 24 hours also do not significanlty alter the levels of Tau and Aβ1-42 [15]. The use of 
manometers during collection can reduce Aβ1-38/40/42 levels, but ultimately does not alter the 
ratio’s measured [16]. Aβ peptides are known to be ‘sticky’ and can be adsorbed to ionic 
surfaces of collection tubes, particularly during serial transfers [12].  
 
With lumbar drain CSF concentrations of Aβ1-42 being reduced by up to 20% there is potential 
for misdiagnosis of Alzheimer’s disease. Furthermore, our findings have important implications 
for clinical research, where lumbar drains are thought to be a more patient friendly method of 
CSF collection when serial samples are needed. This adsorption of Aβ peptides to the luminal 
surface of lumbar drains needs accounting for when interpreting concentrations, to prevent 
misleading diganosis or inaccurate results.  
 
The effect Aβ1-42 peptides adsorption is reduced when CSF is pulled through immediately (5% 
reduction in barium lined lumbar drains). If a diagnosis of Alzheimer’s rests upon the results, 
additional testing with a lumbar puncture would be prudent. We advocate taking the adsorption 
effect into account when writing clinical or research protocols involving lumbar drains and 
analysis of Aβ peptide concentration results.  
 
RESEARCH IN CONTEXT 
1. Systematic review: There are no publications demonstrating the clinical or research 
implications of analysing CSF samples for neurodegenerative proteins, when taken 
from a lumbar drain.  
2. Interpretation: We demonstrate that CSF taken from lumbar drains can have 
artificially low Aβ1-42 concentrations. 
3. Future directions: Both clinical and research protocols analysing CSF Aβ1-42 
concentrations from lumbar drains should acknowledge this potential effect 
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